Michelle Elias

Ms. Michelle Elias

Biophysics, Humboldt-Universität zu Berlin, Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Michelle EliasMichelle Elias
Michelle Elias
Matthias KönigMatthias König
Matthias König
Introduction: Optimizing glimepiride therapy for type 2 diabetes (T2DM) is challenged by pronounced inter-individual variability in pharmacokinetics.Methods: We developed a whole-body physiologically based pharmacokinetic (PBPK) model as a digital twin of glimepiride, enabling systematic evaluation of how patient-specific factors influence drug disposition. Using curated data from 20 clinical studies, the digital twin mechanistically simulates glimepiride’s absorption, distribution, metabolism, and excretion (ADME). It accounts for key determinants of variability including renal and hepatic function, CYP2C9 genotype, and bodyweight.Results: The model accurately reproduced observed pharmacokinetics and quantified these factors’ impact on drug exposure. Increased glimepiride exposure was predicted in individuals with hepatic dysfunction or specific CYP2C9 variants, highlighting substantial genetic and physiological effects.Discussion: This digital twin provides mechanistic insights into pharmacokinetic variability and serves as an in silico platform for exploring individualized dosing and patient stratification strategies, laying the foundation for clinical decision support tools to improve T2DM management.

19 October 2025 in Physiome
Verified
Journal Article
Open access
PDF file
Michelle EliasMichelle Elias
Michelle Elias
Matthias KönigMatthias König
Matthias König
A digital twin in the form of a whole-body physiologically based pharmacokinetic (PBPK) model of glimepiride was developed to systematically evaluate the influence of patient-specific factors on drug disposition. Based on curated data from 20 clinical studies, the model simulates the absorption, distribution, metabolism and excretion (ADME) of the drug while accounting for variability in renal and hepatic function, CYP2C9 genetic variants and bodyweight. The model is implemented in the Systems Biology Markup Language (SBML) standard and simulations are perormed using scripts that utilise the libRoadRunner library to run simulations and generate results. Here, we demonstrate the computational reproducibility of the key findings from the primary publication, thereby verifying the consistency and reproducibility of the model implementation with the published results.

13 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NNNike Nemitz
Nike Nemitz
Michelle EliasMichelle Elias
Michelle Elias
Matthias KönigMatthias König
Matthias König
Dapagliflozin is an SGLT2 inhibitor prescribed for the management of type 2 diabetes mellitus. The drug lowers blood glucose levels by increasing urinary glucose excretion. Despite established efficacy, dapagliflozin demonstrates significant inter-individual variability in pharmacokinetics (PK) and pharmacodynamics (PD), with potential impact on treatment outcomes. To evaluate the sources of variability, we developed a digital twin of dapagliflozin pharmacokinetics and pharmacodynamics built as a PBPK/PD model using curated data from 28 clinical studies. This constitutes a full mechanistic model that integrates absorption, distribution, metabolism, excretion, and pharmacodynamics. It accounts for key determinants of variability including renal and hepatic function, and food effects. The simulations reproduced dose-dependent pharmacokinetics within the therapeutic range and captured inter-individual differences observed in clinical data. Application of the model revealed that renal impairment markedly reduced urinary glucose excretion despite stable plasma exposure, while hepatic impairment had only minor effects. Although food intake decreased peak plasma concentrations without altering overall exposure (AUC), measurable differences in pharmacodynamic response still occurred. The digital twin provides mechanistic insight into PK/PD variability and a platform for optimizing individualized therapy in type 2 diabetes.

26 February 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NNNike Nemitz
Nike Nemitz
Michelle EliasMichelle Elias
Michelle Elias
Matthias KönigMatthias König
Matthias König
Background/Objectives: Dapagliflozin is an SGLT2 inhibitor prescribed for the management of type 2 diabetes mellitus. The drug lowers blood glucose levels by increasing urinary glucose excretion (UGE). Despite established efficacy, dapagliflozin demonstrates significant inter-individual variability in pharmacokinetics (PK) and pharmacodynamics (PD), with potential impact on treatment outcomes. Methods: To evaluate the sources of variability and to support patient stratification and model-informed individualized therapy, we developed a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model of dapagliflozin using curated data from 28 clinical studies. This framework integrates absorption, distribution, metabolism, excretion, and pharmacodynamics, and accounts for key determinants of variability including renal and hepatic function, and food effects. Results: The simulations reproduced dose-dependent pharmacokinetics with predicted Cmax and AUC values typically within 10–15% of observed data. Renal impairment reduced UGE by 40–60% despite modest changes in plasma exposure, while hepatic impairment produced only small shifts in PK and PD. The model also reproduced the fed-state reduction of peak concentrations, consistent with the 30–50% decrease reported clinically. Conclusions: All model files, code, and curated datasets are openly available in line with FAIR standards and Open Science practices, enabling transparent and reproducible analyses and providing a mechanistic basis for individualized therapy in type 2 diabetes.

20 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VTVera Tereshchuk
Vera Tereshchuk
Michelle EliasMichelle Elias
Michelle Elias
MBMariia Babaeva
Mariia Babaeva
Matthias KönigMatthias König
Matthias König
Background/Objectives: Empagliflozin is an SGLT2 inhibitor prescribed for the management of type 2 diabetes mellitus, lowering blood glucose by increasing urinary glucose excretion (UGE) through inhibition of renal glucose reabsorption. PK/PD responses vary substantially across patient populations, complicating dose selection under altered organ function. Here, we developed a whole-body PBPK/PD digital twin integrating absorption, distribution, metabolism, and excretion with explicit modeling of renal glucose handling via the renal threshold for glucose. Methods: The model represents empagliflozin and its glucuronide metabolite, is implemented in SBML, and was calibrated and evaluated against curated PK/PD data from 27 clinical studies spanning healthy individuals, patients with type 2 diabetes, and cohorts with renal or hepatic impairment. Results: The model accurately captured observed clinical PK/PD data across all 27 studies, spanning a wide range of doses, dosing regimens, and patient populations. Good agreement between simulations and observations was obtained under normal and impaired renal and hepatic function, as well as under fasted and fed conditions, demonstrating the model's ability to reproduce empagliflozin disposition and pharmacodynamic response across clinically relevant scenarios. Conclusions: This SBML-based PBPK/PD digital twin provides quantitative insight into empagliflozin dose dependency and the impact of renal impairment, hepatic impairment, and food intake on PK/PD across clinically relevant populations. All model files, simulation scripts, and curated datasets are openly available in accordance with FAIR principles.

17 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Michelle EliasMichelle Elias
Michelle Elias
Matthias KönigMatthias König
Matthias König
Optimizing glimepiride therapy for type 2 diabetes (T2DM) is challenged by pronounced inter-individual variability in pharmacokinetics. To address this, we developed a whole-body physiologically based pharmacokinetic (PBPK) model as a digital twin of glimepiride. This model enables systematic evaluation of how patient-specific factors influence glimepiride disposition, supporting both personalized and stratified treatment approaches. Using curated data from 19 clinical studies, the digital twin was developed to mechanistically simulate glimepiride’s absorption, distribution, metabolism, and excretion (ADME). It accounts for key determinants of patient variability, such as renal and hepatic function, cytochrome P450 2C9 (CYP2C9) genotype, and bodyweight. The model accurately reproduced observed pharmacokinetics and quantified the impact of these factors on drug exposure. For instance, increased glimepiride exposure was predicted in individuals with hepatic dysfunction or specific CYP2C9 variants, highlighting substantial genetic and physiological effects. This digital twin offers mechanistic insights into pharmacokinetic variability and serves as a robust in silico platform for exploring individualized dosing scenarios and patient stratification strategies, laying the foundation for advanced clinical decision support tools to improve T2DM management.